LUT014
LUT014 is a topical inhibitor targeting BRAF that cannot pass through the blood-brain barrier. LUT014 inhibits BRAF kinase and abnormally activates the MAPK/ERK signaling pathway, promoting the proliferation of epidermal keratinocytes, repairing skin barrier damage caused by radiation damage, and alleviating inflammatory responses. LUT014 is independent of RAS signaling and accelerates the repair and regeneration of damaged skin cells. LUT014 can be used to study radiation dermatitis, especially skin damage caused by breast cancer radiotherapy[1][2][3].
Product Specifications
CAS Number
2274819-46-2
UNSPSC
12352005
Hazard Statement
H302, H315, H319, H335
Target
ERK; p38 MAPK; Raf
Type
Reference compound
Related Pathways
MAPK/ERK Pathway; Stem Cell/Wnt
Applications
COVID-19-immunoregulation
Field of Research
Inflammation/Immunology
Assay Protocol
https://www.medchemexpress.com/lut014.html
Purity
97.09
Solubility
DMSO : 50 mg/mL (ultrasonic)
Smiles
FC(F)(F)OC1=CC(NC2=NC=CC3=C2C=CC(C)=C3NC4=NC=CC=C4C5=C6N=CNC6=NC=N5)=CC=C1
Molecular Formula
C27H19F3N8O
Molecular Weight
528.49
Precautions
H302, H315, H319, H335
References & Citations
Shipping Conditions
Room Temperature
Storage Conditions
4°C (Powder, protect from light)
Scientific Category
Reference compound1
Clinical Information
Phase 2
Isoform
B-Raf
Available Sizes
Frequently Asked Questions
Explore Other Products
Browse additional items from our catalog
NKX2.8 (NKX28/2548), CF488A conjugate, 0.1mg/mL
